

One-minute summary

- Incubation period was modelled based on data for 88 confirmed cases of 2019-nCoV who had been in Wuhan but had their infections diagnosed elsewhere after leaving Wuhan.
  - 63 were Wuhan residents who travelled elsewhere; 25 visited Wuhan for a limited time.
- Incubation period was estimated based on known travel history and symptom onset date.
- All cases detected between January 20–28, 2020; at this stage of the outbreak cases were most likely infected in Wuhan.
- Male: 65%; age range: 2-72 years (n=4 missing age).
- Mean incubation period estimated at 6.4 days (95% credible interval 5.6-7.7 days) using the best distribution to fit the data.
- Range of incubation period estimated at 2.1-11.1 days (2.5th-97.5th percentile) using the best distribution to fit the data.
- The authors conclude that “it is prudent not to dismiss the possibility of incubation periods up to 14 days at this stage of the epidemic”.

Additional information

- Travellers included in this study are a select group who may not be representative of all cases.
  - Travellers were more often male and younger than other cases reported.
  - Bias toward more severe cases because the information is based on confirmed cases.
- The epidemic was developing at time of the study (data extracted January 29, 2020), so it is more likely that travellers were infected toward the end of their stay in Wuhan and therefore the estimated upper limit of 11.1 days incubation may be conservative (i.e., may actually be shorter).
- Three distributions were fit to the model, with the best fit reported above.
The distribution with the poorest fit had an incubation period of 2.4-15.5 days (2.5th-97.5th percentile).

The article compares incubation period to other studies of SARS and MERS.

- Estimated mean incubation period very similar to MERS.
- Estimated mean incubation periods for SARS were more variable between studies.
- Supplementary data include line list with age, sex, travel history, and symptom onset.

**PHO reviewer’s comments**

- Following initial publication prior to peer-review [here](#), this updated article has been published in *Eurosurveillance*.

**Citation**


**Disclaimer**

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

**Public Health Ontario**

Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit [publichealthontario.ca](http://publichealthontario.ca).

---